Table 2.
Tumor response after neoadjuvant therapy
| Group | Complete response | Partial response | Stable disease | Progressive disease |
|---|---|---|---|---|
| Total [95% CI] |
3.8% [2.8,5.3] I 2 = 0.0% (n = 36) |
20.9% [15.5,27.6] I 2 = 44.3% (n = 34) |
54.3% [45.9,62.5] I 2 = 45.6% (n = 35) |
16.0% [12.7,19.9] I 2 = 35.8% (n = 35) |
| Resectable [95% CI] |
1.8% [1.0,3.4] I 2 = 0.0% (n = 13) |
14.6% [7.5,26.4] I 2 = 44.3% (n = 12) |
62.2% [46.5,75.7] I 2 = 45.7% (n = 12) |
13.4% [8.4,20.7] I 2 = 36.0% (n = 12) |
| Borderline resectable [95% CI] |
4.9% [3.1,7.7,] I 2 = 9.7% (n = 18) |
28.1% [20.1,37.8] I 2 = 43.9% (n = 18) |
50.5% [40.8,60.2] I 2 = 45.4% (n = 23) |
17.0% [13.0,22.0] I 2 = 36.2% (n = 23) |
| Gemcitabine monotherapya [95% CI] |
2.9% [1.5,5.7] I 2 = 0.0% (n = 6) |
23.5% [6.9,56.0] I 2 = 48.0% (n = 5) |
34.3% [6.3,80.2] I 2 = 48.8% (n = 5) |
15.2% [7.7,27.7] I 2 = 39.8% (n = 5) |
| Non‐gemcitabine monotherapy [95% CI] |
2.0% [0.4,9.4] I 2 = 0.0% (n = 3) |
19.7% [2.9,66.4] I 2 = 46.9% (n = 3) |
48.2% [24.4,72.8] I 2 = 42.8% (n = 3) |
23.8% [13.9,37.5] I 2 = 20.8% (n = 3) |
| Combination therapy [95% CI] |
3.9% [2.5,6.0] I 2 = 6.4% (n = 25) |
22.7% [17.1,29.4] I 2 = 41.6% (n = 14) |
57.1% [49.3,64.5] I 2 = 43.6% (n = 27) |
15.4% [11.8,19.9] I 2 = 36.7% (n = 29) |
| Gemcitabine‐based chemotherapyb [95% CI] |
3.7% [2.5,5.5] I 2 = 9.2% (n = 27) |
23.0% [16.6,30.9] I 2 = 44.5% (n = 25) |
55.9% [46.4,64.9] I 2 = 45.8% (n = 28) |
14.9% [11.2,19.4] I 2 = 37.7% (n = 28) |
| Non‐gemcitabine‐based chemotherapy [95% CI] |
1.8% [0.6,5.0] I 2 = 0.0% (n = 7) |
20.3% [9.9,37.2] I 2 = 43.8% (n = 7) |
47.9% [29.9,66.5] I 2 = 45.1% (n = 7) |
20.4% [14.4,28.0] I 2 = 17.5% (n = 7) |
| Chemotherapy [95% CI] |
1.4% [0.5,3.7] I 2 = 0.0% (n = 8) |
12.7% [8.1,19.5] I 2 = 33.7% (n = 9) |
60.2% [45.2,73.5] I 2 = 45.7% (n = 9) |
14.5% [9.4,21.7] I 2 = 34.7% (n = 9) |
| Chemo + radiotherapy [95% CI] |
4.0% [2.8,5.8] I 2 = 4.9% (n = 28) |
23.8% [16.9,32.3] I 2 = 45.0% (n = 26) |
51.8% [41.6,61.9] I 2 = 45.7% (n = 26) |
16.4% [12.4,21.4] I 2 = 36.8% (n = 26) |
a
We divided the patients into three groups: ① Gemcitabine monotherapy; ② other regimens monotherapy; ③ Combination therapy.
b
The patients were divided into two groups: ① Gemcitabine‐based chemo (including monotherapy and combination therapy); ② other regimens chemotherapy (including monotherapy and combination therapy).